Scott Bramley

[TVR5 @TVR5AVCT]

#AVCT

[Scott Bramley @Bramosh7]

@tom_the_bomb__ @1971bod

[⛏🅾️Ⓜ️💣 @tom_the_bomb__]

#LetsGo #AVCT

[Scott Bramley @Bramosh7]

@caughtsneezing @hughesy0707

[Scott Bramley @Bramosh7]

@SharesAaron @shaunday__ I’ve just had same thing did you get to bottom of it

[Scott Bramley @Bramosh7]

@JStonker Ah okay gotta into my head it was 9.

[Scott Bramley @Bramosh7]

@massivefanNWO @Andrewp37075755 @tom_the_bomb__ Yeah £10 I don’t think so it’s starts at £50

[Scott Bramley @Bramosh7]

#avct Science Day hot off the press

[Avacta @avacta]

We’re pleased to share the recordings from our Science Day. The presentations explore comparative analyses of pre|CISION® payload delivery with AVA6103 vs approved ADCs, alongside updated in vivo studies of the AVA6207 dual payload delivery system. https://t.co/oV0amuV74Q #AVCT

[Mike Wilk @Mike182035]

#AVCT

also different attribution of enhertu and datroway interesting-does prompt the thought that in it's basics it is the Daiichi platform IP under threat

Could be interesting as a lever if Daiich more jv inclined while AZ holding out for licence only?

https://t.co/Dw0hxYU36c

[Scott Bramley @Bramosh7]

@Jenkoool I was expecting update on SGC PFS and potential FDA fast track+hopefully first TNBC data from P1b promised H1 26, science day+ a 2 hr pres seems appropriate. I also think Dec was a damp squib due to PFS going longer than expected hence this science day in close prox with deal 🤞🏻

[TVR5 @TVR5AVCT]

#AVCT

P1b upgraded to 90 patients across x6 indications (from 60 patients across x4 indications previously).

Decision taken to increase size of P1b, just three weeks into clinical dosing of AVA6103.

[Scott Bramley @Bramosh7]

@AndrewDigby3 @Metalhead2525

[Scott Bramley @Bramosh7]

Eventually went through at 79.6p 16:35pm over 3hr to go through

[Scott Bramley @Bramosh7]

Been trying to buy £10k #avct on IG for last hr seem to be ignoring my order chased it up from 79p to 81p as well?

[Christopher Leidli @chrisleidli]

What if chemotherapy could target only the tumor, sparing healthy tissues from harm?

Christina Coughlin, MD, PhD, unveils a revolutionary approach that transforms this dream into reality.

“The idea behind our technology is simple —
Protect healthy tissues from toxic drugs,
and concentrate the treatment directly inside the tumor.

Imagine concentrating treatment in the tumor with up to 100 times the potency found in the bloodstream, enhancing care and hope for patients everywhere.

🎧 Join us in exploring how precision delivery is redefining the future of cancer care in the latest episode of Rx for Biotech, now available on YouTube and all major streaming platforms. platforms.

#podcast #cancer

[BBN @BigBiteNow]

And finally, from this wonderful #AVCT interview.

On AVA6103.

"It's a truly amazing technology. And that's why I mean that this drug entering the clinic right now is really the inflection point for the company, because if those two inventions, the capping group and the linker, those two inventions, actually do what we think it's going to do in patients, watch out, here we come."

[Christina Coughlin @coughlin582]

A great conversation with Christopher Leidli on @RxForBiotech - discussing the future of oncology, innovation and our approach of old drugs new at #AVCT and the next chapter with FOCUS-01
So excited for the future

#FOCUSOnTheWin
#HopeWithoutCompromise

https://t.co/MWLC8tt4vM

[Avacta @avacta]

We are pleased to invite colleagues and investors to our 2026 Science Day: The Next Chapter of pre|CISION. Join us in Central London on May 6 at the Royal Society of Chemistry for presentations followed by a reception. https://t.co/1guKSV8aDY #AVCT